Secondary Dysmenorrhea is characterized by pain, due to a disorder or infection in the woman's reproductive organs; the pain usually begins earlier in the menstrual cycle and lasts upto common menstrual cramps.
Various classes of drugs are used to treat Dysmenorrhea either as monotherpy or as combination therapy. Drug regimen is chosen based on Dysmenorrhea type. Non-steroidal anti-inflammatory drugs (NSAIDs), Glyceryl trinitrate, Progestin regimens and Levonorgestrel intrauterine system (LN-IUS). Surgical options like Laparoscopy, Hysterectomy, Presacral neurectomy, and Laparoscopic uterosacral nerve ablation are also available to treat the condition.
Globally, Dysmenorrhea affects 60-93% of women, of which more than 50% are post pubescent menstruating women. Major factors driving market of Dysmenorrhea are high consciousness level, government campaigns and growing concern about Dysmenorrhea among females. However, long term treatment, morbidity, and traditional family values would restrain the growth of market.
This report provides information on Dysmenorrhea treatment market size for the year 2014-2016, and forecast of the same for year 2021. It also focuses on market drivers, challenges, restraints, market dynamics, growth indicators, competitive landscape, potential growth opportunities and other key aspects with respect to Dysmenorrhea treatment market.
Geographically, USA, Europe and Asia pacific are considered as the major markets for Dysmenorrhea. North America owing has high incidence of Dysmenorrhea. Europe is the second largest market with existence of a large number of Dysmenorrhea patients. North America and Europe have high healthcare spending, well established infrastructure, high awareness about the disease and high availability of its treatments.
Asia-Pacific is expected to have rapid growth in Dysmenorrhea treatment market because of changing infrastructure, educational program, increase in purchasing power, and increased awareness for clinical facilities in the regions. China, Japan, India are the emerging markets they have high market potential for Dysmenorrhea. In these countries growing awareness campaigns is enhancing the Dysmenorrhea treatment market.
This report identifies global Dysmenorrhea treatment market on the basis of type and regional market as follows:
Dysmenorrhea treatment market is segmented based on type primary and secondary
A detailed analysis by region – North America, Europe, Asia Pacific (APAC) and Rest of the World (RoW), has been provided in this report
This report looks into all the major companies operating in the Dysmenorrhea market. Some of the major companies’ profiles are as follows:
Bayer Schering Pharma AG,
Please Note: The report is to be delivered in 1-2 working days after an order is placed.
2. Executive Summary
3. Dysmenorrhea - Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.2.1. Product Benchmarking
3.2.2. End User Profiling
3.2.3. Top 5 Financials Analysis
4. Dysmenorrhea Market- Market Forces
4.1.1. Increasing awareness amongst people
4.1.2. Increasing number of treatment options
4.2.1. Traditional family values
4.5. Porter’s Five Force Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Customers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Degree of Competition
5. Dysmenorrhea Market – Strategic Analysis
5.1. Value Chain Analysis
5.2. Pricing Analysis
5.3. Opportunities Analysis
5.4. Product/Market Life Cycle Analysis
5.5. Suppliers and Distributors
6. Dysmenorrhea Market, By Type
6.1. Primary Dysmenorrhea
6.2. Secondary Dysmenorrhea
7. Dysmenorrhea Market, By Geography
7.2. North America
7.3.6. Rest of Europe
7.4. Asia Pacific
7.4.2. South Korea
7.4.5. Rest of Asia Pacific
8. Market Entropy
8.2. Technological Developments
8.3. Merger & Acquisitions, and Joint Ventures
8.4. Supply - Contract
9. Company Profiles (Introduction, Financials, Key Insights, Key Strategy, Product Portfolio, SWOT Analysis)
9.1. Merck Inc.
9.2. Novartis AG
9.3. Bayer Pharma
9.4. Abbott Healthcare
9.6. Roche pharma
9.7. TAJ Pharma
9.8. Mylan Pharmaceuticals
9.9. Nobel Pharmaceuticals
9.10. Juniper Pharmaceuticals
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
10.3. Research Methodology
10.4. Expert Insights